
Location: Torrance, CA | Employment Type: Full-Time
Own and grow relationships with the world’s leading pharmaceutical companies.
PolyPeptide is expanding its global commercial team and is seeking a Senior Strategic Account Manager to lead and grow relationships with key pharmaceutical and biotech clients across the US. This is a high-impact, strategic role focused on managing top-tier accounts and driving long-term commercial partnerships in a rapidly growing CDMO environment.
As a Senior Strategic Account Manager, you will be responsible for developing and executing account strategies for major pharmaceutical clients, including many of the industry’s top companies. You will act as the primary commercial interface, aligning client needs with PolyPeptide’s global capabilities to drive revenue growth, expand partnerships, and deliver long-term value.
If you are a strategic, relationship-driven commercial leader looking to make an impact at the highest level, we encourage you to apply.
Salary: $160k-$210k
We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity or expression, pregnancy, age, national origin, disability status, genetic information, protected veteran status, or any other characteristic protected by law.

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.
Find out more about our current vacancies at: https://polypeptide.teamtailor.com/